

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Randomised controlled trial of seven COVID-19 vaccines as boosters, breakthrough infections, spike proteins on the Omicron and Delta variants

#### Peer reviewed journals featured:

- A systematic review on the screening value of RT-LAMP and RT-PCR in COVID-19 diagnosis [here](#)
- A randomised controlled trial of seven COVID-19 vaccines as a third dose (booster) following Vaxzevria (AstraZeneca) or Comirnaty (Pfizer) (COV-BOOST) [here](#)
- An observational study on two doses of CoronaVac vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases [here](#)
- Commentary on:
  - Severe breakthrough COVID-19 cases in the Delta variant era [here](#)
  - The Omicron variant [here](#)
  - The WHO international standard for SARS-CoV-2 antibodies to determine markers of protection [here](#)

#### Letters and correspondence discussed:

- Immunogenicity of extended mRNA vaccine dosing intervals [here](#) and associated commentary [here](#)

#### Pre-peer review articles featured:

- Characteristics of cardiovascular disease patients with post-acute sequelae of COVID-19 [here](#)
- Johnson & Johnson (Janssen) or Comirnaty (Pfizer) booster in Comirnaty (Pfizer) vaccinated individuals [here](#)
- S-glycoprotein diversity of the Omicron variant [here](#)
- COVID-19 impact on mental sequelae in families [here](#)
- A comparative study of spike protein on the Omicron and Delta variant [here](#)
- Third COVID-19 vaccine dose boosts neutralising antibodies in poor responders [here](#)
- Third booster dose in fully immunised healthy adults with CoronaVac vaccine [here](#)

## Guidance and reports

- The World Health Organization published:
  - A SARS-CoV-2 Omicron variant assays and animal models study tracker [here](#)
  - An update of its COVID-19 core case report form (CRF) [here](#)
- The UK Health Security Agency published an update on SARS-CoV-2 variants of concern and variants under investigation including Omicron variant [here](#), and risk assessment for Omicron [here](#)
- The Therapeutic Goods Administration (TGA) issued provisional approval to Pfizer (COMIRNATY) for use in children aged 5 years and over [here](#)

## News and blogs

- South Africa's surge in cases deepens alarm over Omicron variant [here](#)
- Success of vaccination programme in reaching ethnic minority groups in the UK [here](#)
- A podcast on how COVID-19 has impacted mental health [here](#)

[Click here](#) to subscribe to the daily evidence digest.

### Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).